Navigation Links
Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 46th American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

in the bone marrow. In the United States, more than 50,000 people are living with MM and approximately 20,000 new cases are diagnosed annually.(i) Worldwide, more than 180,000 people are living with MM and approximately 86,000 new cases are diagnosed annually.(ii)

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801 is a targeted alpha-folate inhibitor currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

Forward Looking Statements

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws.  These forward-looking statements include without limitat
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015  Web Industries, Inc., a leading provider ... Medical Device, Advanced Composites, Consumer Products, and Wire ... Medical Specialties Preferred Converter by 3M,s Medical Specialties ... to streamline their supply chains by using Web ... materials, intermediate converting services, and contract manufacturing and ...
(Date:3/3/2015)... , March 3, 2015  AT&T 1 ... today announced that  AT&T  is the connectivity provider for ... was designed to help provide peace of mind to ... the freedom to live active lives with the confidence ... need it. The AT&T network 2 helps power ...
(Date:3/3/2015)... 3, 2015  Cyberonics, Inc. (NASDAQ: CYBX ... treatment and management of epilepsy, today announced it will ... March 11, 2015, in Miami . ... Chief Executive Officer, will speak at 1:05 PM Eastern ... chat format, and no formal materials will be presented.  ...
Breaking Medicine Technology:Web Industries Receives 3M Preferred Converter Status 2AT&T Providing Connectivity for Philips GoSafe Mobile Medical Alert System, Empowering United States Seniors to be Connected to Emergency Care On-the-Go 2AT&T Providing Connectivity for Philips GoSafe Mobile Medical Alert System, Empowering United States Seniors to be Connected to Emergency Care On-the-Go 3AT&T Providing Connectivity for Philips GoSafe Mobile Medical Alert System, Empowering United States Seniors to be Connected to Emergency Care On-the-Go 4
... Data presented at AACR 2008, SAN DIEGO, ... owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq,and ... demonstrating that,the Company,s experimental drug candidate, brostallicin, killed ... status. The study, conducted,by Cristina Geroni, Ph.D., et ...
... Inc.,(Nasdaq: MITI ), a biopharmaceutical company developing ... autoimmune diseases, today,presented at the Annual Meeting of ... Diego, CA, preclinical data of two new human ... of acute myelogenous,leukaemia (AML) and melanoma (1). BiTE ...
Cached Medicine Technology:Preclinical Study Shows CTI's Brostallicin's Cancer-Killing Ability Based on Genetic Profiling 2Preclinical Study Shows CTI's Brostallicin's Cancer-Killing Ability Based on Genetic Profiling 3Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma 2Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma 3Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma 4Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma 5
(Date:3/3/2015)... York (PRWEB) March 03, 2015 ... used to market the atypical antipsychotic medication continue ... According to court documents, the South Carolina Supreme ... that Johnson & Johnson’s Janssen Pharmaceuticals unit had ... risks. However, while the Court’s February 25th decision ...
(Date:3/3/2015)... Longtime parent visionary and inspiring new father, Lucas ... for a candid interview on the surrogacy process in ... revelation of his magical surrogacy journey — detailing the ... the birth of his precious twin girls. , ... Founder of CARE stated, “We are committed to maintaining ...
(Date:3/3/2015)... Man, Woman & Student of the Year ... and ensure access to treatments for blood cancer patients, ... their families. Through this annual national ten-week campaign, individuals ... a world without blood cancers. The national titles will ... to be announced this summer. To date, these dedicated ...
(Date:3/3/2015)... SC (PRWEB) March 03, 2015 The ... the public’s expectation of excellence in care and safe ... the position of the RNS that biologic infusions are ... under the direct supervision of a registered nurse (RN), ... reactions, including anaphylaxis can occur in patients receiving these ...
(Date:3/3/2015)... The human augmentation market is mainly driven ... wearable augmentation sector is predicted to outpace the in-built ... years. , The eye-wear sector dominates the North ... of new products launches in the region. Furthermore, strong ... as well as the rising demand for advantageous products ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Ruling Upholding South Carolina Jury Decision in Risperdal Marketing Case 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Ruling Upholding South Carolina Jury Decision in Risperdal Marketing Case 3Health News:CARE Surrogacy Center Mexico Conducts Candid Interview with Australian Father of Twins 2Health News:CARE Surrogacy Center Mexico Conducts Candid Interview with Australian Father of Twins 3Health News:The Leukemia & Lymphoma Society’s Oregon and SW Washington Chapter Kicks Off Their Eleventh Annual Man, Woman & Student of the Year Campaign 2Health News:The Leukemia & Lymphoma Society’s Oregon and SW Washington Chapter Kicks Off Their Eleventh Annual Man, Woman & Student of the Year Campaign 3Health News:Administration of Biologic Infusions: A Position Statement of the Rheumatology Nurses Society 2Health News:Human Augmentation Market to Pose 43.5% CAGR Through 2020, States MarketsandMarkets in its New Research Study Now Available at MarketPublishers.com 2
... The American Association for Dental Research (AADR) has ... AADR William B. Clark Fellowship in Clinical Research. This ... Meeting & Exhibition in Washington, DC, March 3, 2010. ... Department of Periodontics, University of Texas, Health Science at ...
... ... children and we are working with our members to develop new tools to keep the ... ... International Consumer Product Health & Safety Organization’s (ICPHSO) CPSC Day in Washington, D.C. on February ...
... radiation may not be necessary for early malignancy, study ... alone offers a reasonable overall level of survival for ... new study suggests. , Traditional treatment regimens for limited ... study, researchers analyzed U.S. National Cancer Institute data on ...
... , ... ... ... ...
... ... vitamin and supplement retailer recently launched a robust health encyclopedia offering health news and ... knowledge and more. , ... Shelby Township, Mich. (PRWEB) February 19, 2010 -- eVitamins™, a leading online retailer ...
... Ecological, physiological similarities provide basis for insights, expert says, ... that dolphins suffer from diseases similar to those found ... on the effects that contaminated water and seafood have ... and their diet includes much of the same seafood ...
Cached Medicine News:Health News:JPMA Supports CPSC Chairman Tenenbaum's Continued Safety Efforts 2Health News:JPMA Supports CPSC Chairman Tenenbaum's Continued Safety Efforts 3Health News:JPMA Supports CPSC Chairman Tenenbaum's Continued Safety Efforts 4Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 3Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 4Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 5Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 6Health News:eVitamins Launches New Health Encyclopedia 2Health News:Dolphins May Warn of Health Risks in Humans 2
... Latex Foley Catheter, Smooth, non-stick silicone ... but flexible, latex-based construction with large ... round tip with two opposing eyes ... two staggered eyes and a 30cc ...
... 3-way design permits continuous irrigation ... in the Foley Catheter. 3-Way ... construction, as well as LUBRICATH ... variety of models including Suggs, ...
Red Latex Bardex I.C. Foley 2-Way Catheter (Council Model)...
All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: